Uncover the Bispecific Highlights from ASCO 2026

Bispecific momentum is accelerating. At ASCO 2026, 182 bispecific‑relevant abstracts were identified – a 37% increase year-on-year!

This PDF report distils that surge into clear, actionable insight, helping you quickly see where clinical progress is happening, which targets are advancing, and how the competitive landscape is shifting. Download your complimentary copy below.

What Changed for Bispecifics This Year?

This year’s dataset is less about early signals, more about delivery. 96% of abstracts were clinical, with most tied to trial data – giving a far clearer read on what’s working and what isn’t.

The analysis strips away the volume and leaves you with structured, decision-ready insight you can act on immediately.

 

Highlights from this year’s report:

  • Clinical expansion: 168 trials represented, a 27% increase YoY
  • Late-stage progress: Phase 3 activity has nearly doubled
  • Target focus: PD‑L1 (+62.5%) and EGFR (+37.5%) gain traction alongside CD3 and PD‑1
  • Solid tumours dominate with 30 abstracts (+50% YoY)
  • Proven biology still leads: Established target pairs continue to dominate late-stage pipelines
Download the report to read the full story.

You May Also Be Interested In…

Learn More About Bispecific

What is Beacon Bispecific?
  • The Most Comprehensive Way to Search the Bispecific Drug Development Landscape: Unique search ontologies based on Bispecific drug and trial characteristics
  • Market Leading Approach to Bispecific Preclinical & Clinical Data Curation: Manual curation of key Bispecific research and development data points Bispecific research scientists
  • Seamlessly Integrate Commercial & Scientific Data all in One Place: Search Bispecific company and deal data based on their pipeline and technologies.
  • Unrivalled Granularity in Reports & Analysis: Our search ontology and technology indexing enable comprehensive analysis not seen elsewhere.
Learn More About Beacon Bispecific Request Demo

What is Beacon?

Beacon is the essential intelligence platform for R&D decision-makers working in pharma and biotech, offering unique technology and drug datasets for complex therapeutics and disease areas.

Our market-defining proprietary ontologies, manual data curation, and accurate and comprehensive life science data, provide our customers with unparalleled visibility of the drug, trial and commercial landscape.

This is why 24 of the top 25 pharmaceutical companies trust Beacon to power their critical pipeline, competitive, and commercial decisions.

We’d welcome the opportunity to show you how Beacon can transform your data strategy. Book your personalized demonstration today!

Request Demonstration

Menu
Search Icon
Close Icon
Search